Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
14,82 USD | +5,11% | -3,52% | +82,29% |
Omzet 2024 * | 161 mln. 150 mln. | Omzet 2025 * | 413 mln. 383 mln. | Marktkapitalisatie | 4,14 mld. 3,84 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -352 mln. -327 mln. | Nettowinst (verlies) 2025 * | -245 mln. -227 mln. | EV/omzet 2024 * | 24,8 x |
Nettoliquiditeiten 2024 * | 133 mln. 124 mln. | Nettoliquiditeiten 2025 * | 251 mln. 232 mln. | EV/omzet 2025 * | 9,42 x |
K/w-verhouding 2024 * |
-11,4
x | K/w-verhouding 2025 * |
-20,6
x | Werknemers | 557 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,71% |
Recentste transcriptie over Iovance Biotherapeutics, Inc.
1 dag | +5,11% | ||
1 week | -3,52% | ||
Lopende maand | -6,85% | ||
1 maand | -14,97% | ||
3 maanden | +72,73% | ||
6 maanden | +225,00% | ||
Lopend jaar | +82,29% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 30-09-16 |
Director of Finance/CFO | 51 | 14-12-20 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 20-07-11 |
Director/Board Member | 56 | 07-06-16 | |
Michael Weiser
BRD | Director/Board Member | 61 | 15-03-18 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.95% | 11 M€ | -6,03% | - | |
0.93% | 0 M€ | 0,00% | - | |
0.14% | 0 M€ | 0,00% | - | |
0.11% | 2 M€ | -.--% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-03-24 | 14,82 | +5,11% | 6 187 850 |
27-03-24 | 14,1 | +0,36% | 4 111 414 |
26-03-24 | 14,05 | -3,30% | 5 101 022 |
25-03-24 | 14,53 | -3,26% | 4 574 683 |
22-03-24 | 15,02 | -2,21% | 3 694 385 |
uitgestelde koers Nasdaq, 28 maart 2024 om 21:30 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+82,29% | 4,14 mld. | |
-6,65% | 12,54 mld. | |
-14,23% | 2,34 mld. | |
-23,73% | 2,51 mld. | |
-19,45% | 1,66 mld. | |
+32,37% | 1,15 mld. | |
+7,42% | 840 mln. | |
-11,75% | 548 mln. | |
-34,49% | 466 mln. | |
+42,88% | 277 mln. |